The mechanisms include: CDK4/6 inhibitors reduce the proliferation of immunosuppressive T-reg cells (76), increase tumor antigen presentation in breast cancer cells, stimulate type III IFN production (76), and promote the infiltration and activation of T-cells. This evidence concerns the gene CDK4 and neoplasm.